- Home
- STG vs TCRX Comparison
STG vs TCRX Comparison
Compare STG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | TCRX |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 57.9M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STG | TCRX |
|---|---|---|
| Price | $4.65 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 2.3K | ★ 479.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,816,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.28 | $0.88 |
| 52 Week High | $15.00 | $2.57 |
Technical Indicators
Market Signals| Indicator | STG | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 51.47 |
| Support Level | $4.35 | $0.91 |
| Resistance Level | $5.19 | $1.08 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 35.71 | 83.78 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.